CollabRx and Collaborators at Leading Academic Centers

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology

SAN FRANCISCO, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- via PRWEB - CollabRx, Inc. (Nasdaq: CLRX ), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 The publication titled "A framework for genomic biomarker actionability and its use in clinical decision making" was co-authored by senior members of CollabRx's scientific team in collaboration with clinical researchers and physicians at the University of California, San Diego, the University of Texas MD Anderson Cancer Center, the Huntsman Cancer Institute, Banner MD Anderson Cancer Center, and the Vall d'Hebron Institut d'Oncologia, Universitat Autonoma of Barcelona.

Large-scale genetic testing using next-generation sequencing (NGS) is increasingly being used to inform the care of cancer patients by physicians who wish to consider a targeted therapy approach to treatment planning. Formal clinical treatment guidelines exist for tumor genetic mutations in a relatively small number of genes and cancer types (e.g. BRAF mutations in melanoma). Treatment guidelines do not exist for the vast majority of tumor genomic abnormalities that are being discovered using large-scale NGS panels that evaluate hundreds of genes at a time. Moreover, many physicians lack the ability to prioritize among multiple genetic alterations for clinical actionability. Consequently, physicians and their patients cannot easily determine which genetic alteration among potentially many may be the most clinically relevant and thus could be used to guide treatment planning.

The publication announced today describes an objective evidenced-based framework that relates the biological basis of tumor genetic mutations in a given gene to the clinical rationale for treating a patient with potentially relevant FDA-approved or investigational drugs that are associated with the mutation based on published medical and scientific data. Relevant data span a spectrum of clinical strength of evidence and can enable physicians to categorize the clinical actionability of genetic alterations.

"The framework described in the publication forms the core of CollabRx's Genetic Variant Annotation (GVA) Service™ which can be used to support physician decision-making by associating specific genes, mutations, and cancer types with published evidence linking these mutations with drugs, drug classes, and/or drug combinations," said Smruti Vidwans, Ph.D., CollabRx chief scientist and lead author of the publication. "This information is essential to informing cancer treatment planning at the point of care by leveraging a tumor's unique genetic profile."

"This important actionability framework provides a standard lens through which to view precision oncology by making complex NGS-based cancer panel results more useful to physicians who treat cancer patients," said George Lundberg, M.D., CollabRx editor-in-chief and chief medical officer who was not an author of the publication. "The authors of this publication have thought deeply about the important information needed for physicians to use genetic testing of tumors in the care of cancer patients."

CollabRx representatives will be available to discuss this publication and the GVA Service at the 2014 Association for Molecular Pathology (AMP) Annual Meeting taking place November 12-15, 2014 in National Harbor, MD.

About CollabRx

CollabRx, Inc. (Nasdaq: CLRX ) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com .

About the CollabRx GVA Service

The GVA Service offered by CollabRx is a widely used, highly scalable, and cloud-based electronic decision support system that provides a turn-key analysis of many types of genetic alterations in cancer. The GVA Service accepts genetic data from any source or platform and pairs it with information contained in a knowledge base that includes the clinical impact of specific genetic profiles. The CollabRx knowledge base is supported by a proprietary technology platform and expert system that leverages a large and growing network of over 75 thought-leaders and clinical practitioners in the United States and Europe who work together with CollabRx to develop new tools for clinical decision-making in oncology. The GVA Service is offered to customers in a Software as a Service (SaaS) business model.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

1. Vidwans, S.J. et al. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014 Oct 22. [Epub ahead of print]; http://www.impactjournals.com/oncoscience/fil.../90/90.pdf

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/11/prweb12303483.htm

CollabRx, Inc. Gavin Gordon +1 415-248-5350

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 0

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 91

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 109

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 48

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 85

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 196

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 75

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Broadwind to Host Q4 and Year-End 2024 Financial Results Call

Updated Category News Views 173

Broadwind Announces Financial Results Conference Call Broadwind (NASDAQ: BWEN), a prominent manufacturer in the clean tech sector, is preparing to share its financial performance for the fourth quarter and the entirety of 2024. The company will release its earnings report on March 5, just before the markets open. Investors and analysts alike are keen to gain insights into...

Continue Reading
Becker Milk Company Limited Shares Financial Highlights

Updated Category News Views 188

Becker Milk Company Limited Announces Financial Results Becker Milk Company Limited (TSX-BEK.B) recently announced its financial results for the quarter ended July 31, 2025. The company has demonstrated resilience in a competitive market while maintaining a commitment to its shareholders by declaring a regular dividend. Financial Performance Overview The financial results...

Continue Reading
Pembroke VCT Expedites B Ordinary Shares Issuance

Updated Category News Views 149

Pembroke VCT Enhances Shareholder Value with New Issuance Pembroke VCT plc has made a significant move by allotting 5,061,629 B Ordinary Shares through its current subscription offer, targeting a potential raise of £60 million in capital. These shares were priced between 102.23p to 108.24p, based on the unaudited net asset value from the end of September 2024. This...

Continue Reading
FASTSIGNS Convention 2025: Celebrating Franchise Growth

Updated Category News Views 472

FASTSIGNS 2025 International Convention Highlights Expert keynotes and engaging networking sessions took center stage at the recent FASTSIGNS International Convention. This year's theme, "Be All In," set an energizing tone for the event dedicated to honoring franchisee achievements and showcasing the brand's growth in sales, profitability, and locations. Attendance and...

Continue Reading
Pyxus International Gears Up for Earnings Call

Updated Category News Views 23

Pyxus Prepares for Earnings Call with Stakeholders In the tangled world of agricultural stocks, there's always one company that catches your eye when it's earning season, and right now, that's Pyxus International (OTCID: PYYX). This North Carolina-based player, a stalwart in the agricultural sector, has set the date to drop their financial numbers on June 4, 2026. Now, if...

Continue Reading